
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics is a promising company with valuable products and potential market opportunities in the treatment of neurological diseases. Its current product, SER-252, has shown promising results in clinical trials, and the company's POZ platform has the potential to revolutionize drug delivery in this industry. With successful Phase 1b results and potential for future partnerships, Serina may see significant growth and success in the future as it addresses a pressing need for better treatments in the Parkinson's disease market.
Bears say
Serina Therapeutics is a clinical-stage biotechnology company with a negative outlook due to its focus on a single product candidate, SER-252, for advanced Parkinson's disease. While the market for this product is large and in need of better treatment options, the company faces significant regulatory and technical challenges with its proprietary POZ polymer drug delivery platform. Furthermore, the company's pipeline is limited beyond SER-252 and it is dependent on a single source of revenue from grant funding. This, combined with its recent clinical hold and potential for future delays, make Serina Therapeutics a high-risk, low-reward investment.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares